Compare H2O America (HTO) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Organon & Co. Common Stock — how do they compare? H2O America trades at $57.8 (market cap $2.40B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and H2O America pays the higher dividend (3.07%). Which is the better fit depends on your goals — on Pluang, investors hold H2O America for 39 Days and Organon & Co. Common Stock for 0 Days on average.
| HTO | OGN | |
|---|---|---|
Market Cap | $2.40B | $3.61B |
Volume | 620,902 | 1,808,049 |
Sector | Utilities | Health |
52-Week High | $65.43 | $13.81 |
52-Week Low | $44.44 | $5.70 |
Typical Hold Time | 39 Days | 0 Days |
Enterprise Value | $4.19B | $11.03B |
Dividend Yield | 3.07% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $58.49, down 0.27% on the day, with a bearish technical signal but strong analyst support. Recent earnings show mixed quarterly beats, with Q2 2026 adjusted EPS of $0.72 beating expectations. The company completed the acquisition of Quadvest via its Texas subsidiary, expanding its regulated water utility footprint. Financials indicate steady revenue growth to $829 million in 2026 and a net income margin of 12.9%, supported by a gross profit margin of 56.91%.
The stock presents a compelling opportunity with a consensus price target of $66.50, implying over 13% upside, and 83% of analysts rate it a Buy. However, risks include execution challenges from recent acquisitions, potential EPS dilution, and a high investing cash outflow. The bearish technical trend near key support at $58 requires monitoring for stability.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
